Lung Cancer Drugs Market 2020 Business Scenario with Recent Trends, Size, Share, Statistics, Competition Strategies, Application, Region and Forecast Analysis by 2030

The Business Research Company offers "Lung Cancer Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trends and strategies that players in the market can adopt.

The global lung cancer drugs market is expected to decline from $8.9 billion in 2019 to $7.6 billion in 2020 at a compound annual growth rate (CAGR) of -15.3%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. Hospitals across the world have postponed the chemo treatments for cancer patients due to covid positive cases in the hospitals. The sessions are delayed or postponed to prevent patients and staff from unnecessary exposure. The cancer treatment can lower the patient`s ability to fight infection. COVID-19 pandemic is affecting industries across the globe including the pharmaceutical sector. The disruptions due to extended factory closures in various countries, shortage of APIs and other chemicals, rise in prices of key ingredients, and slowed production are the key factors for this decline. The market is then expected to recover and grow at a CAGR of 10.9% from 2021 and reach $12.4 billion in 2023.

Place a DIRECT PURCHASE ORDER of The Entire 140+ Pages Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2567

The lung cancer drugs market consists of sales of lung cancer drugs. Lung cancer is a type of cancer that decreases the ability of lungs to supply oxygen to the bloodstream beacause of uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy and targeted therapy. On the basis of the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

The rising prevalence rate of lung cancer is a major driver for the lung cancer market. This is mainly because an increase in prevalence and incidence rate of lung cancer cases propels the need for drugs that enable effecient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. According to the International Agency for Research on Cancer (IARC), cancer led to around 9.6 million deaths in 2018, out of which, lung cancer was responsible for the largest number of deaths (1.8 million deaths, 18.4% of the total).

Lung Cancer Drugs Market Segmentation: -
By Disease Type
Small cell lung cancer (SCLC)
Non-small cell lung cancer (NSCLC)

By End User
Hospitals
Clinics
Others

By Drugs
Gemzar
Paraplatin
Taxotere
Navelbine
Avastin
Tarceva
Iressa
Others

Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Few Points From Table Of Content
1. Executive Summary
2. Lung Cancer Drugs Market Characteristics
3. Lung Cancer Drugs Market Size And Growth
4. Lung Cancer Drugs Market Segmentation
5. Lung Cancer Drugs Market Regional And Country Analysis
.
.
.
25. Lung Cancer Drugs Market Competitive Landscape And Company Profiles
26. Key Mergers And Acquisitions In The Lung Cancer Drugs Market
27. Lung Cancer Drugs Market Trends And Strategies
28. Product Pipeline Analysis
29. Lung Cancer Drugs Market Future Outlook and Potential Analysis
30. Appendix

The report covers the trends and market dynamics of the Lung Cancer Drugs Market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Request for a Sample Copy of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2567&type=smp

Some of the key players involved in the Lung Cancer Drugs Market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., GlaxoSmithKlin

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

This release was published on openPR.